Modality
ASO
MOA
AuroraAi
Target
PLK4
Pathway
STING
HS
Development Pipeline
Preclinical
~Sep 2013
→ ~Dec 2014
Phase 1
~Mar 2015
→ ~Jun 2016
Phase 2
~Sep 2016
→ ~Dec 2017
Phase 3
Mar 2018
→ Apr 2031
Phase 3Current
NCT06051495
2,513 pts·HS
2018-09→2031-04·Active
NCT03417147
2,672 pts·HS
2018-03→2025-06·Terminated
NCT05130679
2,176 pts·HS
2025-05→2025-10·Active
7,361 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-06-169mo agoPh3 Readout· HS
2025-10-265mo agoPh3 Readout· HS
2026-07-274mo awayBTD· HS
2031-04-115.0y awayPh3 Readout· HS
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P3
Termina…
P3
Active
P3
Active
Catalysts
Ph3 Readout
2025-06-16 · 9mo ago
HS
Ph3 Readout
2025-10-26 · 5mo ago
HS
BTD
2026-07-27 · 4mo away
HS
Ph3 Readout
2031-04-11 · 5.0y away
HS
ActiveTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06051495 | Phase 3 | HS | Active | 2513 | ORR |
| NCT03417147 | Phase 3 | HS | Terminated | 2672 | UPDRS |
| NCT05130679 | Phase 3 | HS | Active | 2176 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR |